ESC 365 - Effects of dapagliflozin on new-onset diabetes in patients with heart failure: a pooled, participant-level analysis of the DAPA-HF and DELIVER trials

HF 2024 Premium Access

Effects of dapagliflozin on new-onset diabetes in patients with heart failure: a pooled, participant-level analysis of the DAPA-HF and DELIVER trials

Session: Young Investigator Award (YIA) Clinical Cardiology

Topic: Pharmacotherapy

Speaker: Doctor M. Lassen (Boston, US)

Event: Heart Failure 2024

Congress Presentation

About the speaker

Doctor Mats Christian Hoejbjerg Lassen

Brigham and Women's Hospital, Heart and Vascular Center, Boston (United States of America)

1 follower

3 more presentations in this session

Tricuspid regurgitation disease stages and treatment outcomes after transcatheter tricuspid valve repair

Speaker: Doctor F. Schlotter (Mainz, DE)

Heart Failure and autoimmune disease: a Nationwide Cohort Study

Speaker: Ms G. Sun (Copenhagen, DK)

Can SGLT2i use decrease the risk of atrial fibrillation in patients with heart failure with reduced ejection fraction: a retrospective cohort study

Speaker: Doctor J. Alejandro (Baltimore, US)

Access the full session

Young Investigator Award (YIA) Clinical Cardiology

Speakers: Doctor M. Lassen, Doctor F. Schlotter, Ms G. Sun, Doctor J. Alejandro

About the event

Heart Failure 2024

11 May - 14 May 2024

Sessions Presentations

Congress

ESC 365 is supported by